VolitionRx study validates Nu.Q NETs H3.1 biomarker as predictor of 28-day sepsis mortality, RRT need

PUBT · 1d ago
VolitionRx study validates Nu.Q NETs H3.1 biomarker as predictor of 28-day sepsis mortality, RRT need
  • VolitionRx reported peer-reviewed clinical validation for its Nu.Q NETs H3.1 sepsis biomarker, published in Critical Care Medicine.
  • Results were presented now via publication, not flagged for a future conference readout.
  • Study concluded the biomarker can independently flag higher-risk sepsis patients, supporting earlier clinical decisions on organ support.
  • Management framed the data as strengthening licensing talks with diagnostics partners across a sepsis market it sizes at USD 2.8 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608260817PR_NEWS_USPR_____LN34052) on August 26, 2026, and is solely responsible for the information contained therein.